Mouse anti-Human HLADR Monoclonal Antibody | anti-HLADR antibody

Monoclonal Antibody to HLADR (Clone: AB3)

Cat. Num. AAA669223

• Gene Names: HLA-DRA; HLA-DRA1
• Reactivity: Human
• Applications: Flow Cytometry, Functional Assay
• Purity: Protein G Chromatography Purified
• Synonyms: HLADR; Monoclonal Antibody; Monoclonal Antibody to HLADR (Clone: AB3); anti-HLADR antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG2a
• Clone Number: AB3
• Purity/Purification: Protein G Chromatography Purified
• Form/Format: 100 ug in 200 ul PBS containing 0.05% BSA and 0.05% sodium azide. Sodium azide is highly toxic.
• Sequence Length: 254

• Applicable Applications for anti-HLADR antibody: Flow Cytometry (FC/FACS)
• Application Notes: FC/FACS: 0.5-1 ug/10^6 Cells
• Immunogen: HLA-DRA
• Conjugation: Unconjugated

Flow Cytometry (FC/FACS)

(Fig.1: Cell surface staining of PBMC (lymphocytes gated). Green Isotope control. Red HLADR, clone AB3. 0.2 ug antibodies were used. Goat anti-mouse IgG PE was used as secondary antibody.)

Related Product Information for anti-HLADR antibody

The HLA-DRA gene at 6p21.3 is one of the HLA class II alpha chain paralogues, and it plays a central role in the immune system by presenting peptides derived from extracellular proteins. Unlike the alpha chains of other Human MHC class II molecules, the alpha subunit is practically invariable. The promoter for the HLA-DRA is the most well studied, and it contains sites, from 5' to 3' , for the trimeric RFX, CREB, the trimeric NF-Y, Oct-1, and YY1. RFX, CREB, and NF-Y contribute to the binding of the CIITA co-activator, which is either constitutively expressed in cells that constitutively express the MHC class II genes, or is induced by IFN-gamma activation of STAT1alpha. The beta-2 domain of the conserved HLA-DR alpha molecule encoded by the HLA-DRA1 locus interacts with the CD4 molecule in human lymphocytes. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages).

Product Categories/Family for anti-HLADR antibody

Immunology

NCBI and Uniprot Product Information

• NCBI GI #: 52426774
• NCBI GeneID: 3122
• NCBI Accession #: NP_061984.2
• NCBI GenBank Nucleotide #: NM_019111.4
• UniProt Accession #: P01903; Q30160; Q6IAZ1; Q861I2; Q9TP70; A2BET4
• Molecular Weight: 28,607 Da
• NCBI Official Full Name: HLA class II histocompatibility antigen, DR alpha chain
• NCBI Official Synonym Full Names: major histocompatibility complex, class II, DR alpha
• NCBI Official Symbol: HLA-DRA
• NCBI Official Synonym Symbols: HLA-DRA1
• NCBI Protein Information: HLA class II histocompatibility antigen, DR alpha chain
• UniProt Protein Name: HLA class II histocompatibility antigen, DR alpha chain
• UniProt Gene Name: HLA-DRA
• UniProt Synonym Gene Names: HLA-DRA1

NCBI Description

HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5. [provided by RefSeq, Jul 2008]

Uniprot Description

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.